Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy
ABSTRACT Introduction Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. Although Delta‐like ligand 3 (DLL3) is specifically expressed on the surface of SCLC, the association of DLL3 with prognosis in SCLC remains uncertain. Hence, we aimed to evaluate prognos...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15522 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576780516458496 |
|---|---|
| author | Hohyung Nam Soon‐Hee Jung Jii Bum Lee Jee Hyun Kong Seungtaek Lim |
| author_facet | Hohyung Nam Soon‐Hee Jung Jii Bum Lee Jee Hyun Kong Seungtaek Lim |
| author_sort | Hohyung Nam |
| collection | DOAJ |
| description | ABSTRACT Introduction Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. Although Delta‐like ligand 3 (DLL3) is specifically expressed on the surface of SCLC, the association of DLL3 with prognosis in SCLC remains uncertain. Hence, we aimed to evaluate prognostic role of DLL3 in extensive stage of SCLC treated with first‐line chemotherapy. Materials and Methods A total of 54 patients with extensive stage of SCLC (ES‐SCLC) who were treated with first‐line chemotherapy were included for our analysis. In addition, tissue specimen should be available for immuno‐histochemical staining for DLL3, and their clinico‐pathologic data, including progression‐free survival (PFS) and overall survival (OS), were obtained. DLL3 expression and the percentage of tumor cells with DLL3 positive among total cancer cells were analyzed microscopically and DLL3 high and DLL3 low were defined as the percentage of DLL3 positive tumor cells versus total cancer cells ≧ 75% and < 75%, respectively. Results DLL3 expression was not associated with any of the clinico‐pathological characteristics such as age at diagnosis, sex, response to first‐line chemotherapy, second‐line chemotherapy (Yes or No), and number of metastatic sites. However, response to first‐line chemotherapy and number of metastatic sites were correlated to PFS, while DLL3 expression and number of metastatic sites were correlated to OS. Conclusion DLL3 was highly expressed in SCLC, and not associated with any clinico‐pathological characteristics. In survival outcome, DLL3 was correlated with worse OS, which suggests the prognostic role of DLL3 in ES‐SCLC. |
| format | Article |
| id | doaj-art-bc8c1b5d3ccf4af9aee5cf0bf961bf7f |
| institution | Kabale University |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-bc8c1b5d3ccf4af9aee5cf0bf961bf7f2025-01-30T22:40:34ZengWileyThoracic Cancer1759-77061759-77142025-01-01162n/an/a10.1111/1759-7714.15522Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line ChemotherapyHohyung Nam0Soon‐Hee Jung1Jii Bum Lee2Jee Hyun Kong3Seungtaek Lim4Department of Hematology, Seoul St. Mary's Hospital, College of Medicine Catholic University Seoul Republic of KoreaDepartment of Pathology Yonsei University Wonju College of Medicine Wonju Republic of KoreaDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center Yonsei University College of Medicine Seoul Republic of KoreaDepartment of Hematology‐Oncology, Division of Internal Medicine, Wonju Severance Christian Hospital Yonsei University Wonju College of Medicine Wonju KoreaDepartment of Hematology‐Oncology, Division of Internal Medicine, Wonju Severance Christian Hospital Yonsei University Wonju College of Medicine Wonju KoreaABSTRACT Introduction Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. Although Delta‐like ligand 3 (DLL3) is specifically expressed on the surface of SCLC, the association of DLL3 with prognosis in SCLC remains uncertain. Hence, we aimed to evaluate prognostic role of DLL3 in extensive stage of SCLC treated with first‐line chemotherapy. Materials and Methods A total of 54 patients with extensive stage of SCLC (ES‐SCLC) who were treated with first‐line chemotherapy were included for our analysis. In addition, tissue specimen should be available for immuno‐histochemical staining for DLL3, and their clinico‐pathologic data, including progression‐free survival (PFS) and overall survival (OS), were obtained. DLL3 expression and the percentage of tumor cells with DLL3 positive among total cancer cells were analyzed microscopically and DLL3 high and DLL3 low were defined as the percentage of DLL3 positive tumor cells versus total cancer cells ≧ 75% and < 75%, respectively. Results DLL3 expression was not associated with any of the clinico‐pathological characteristics such as age at diagnosis, sex, response to first‐line chemotherapy, second‐line chemotherapy (Yes or No), and number of metastatic sites. However, response to first‐line chemotherapy and number of metastatic sites were correlated to PFS, while DLL3 expression and number of metastatic sites were correlated to OS. Conclusion DLL3 was highly expressed in SCLC, and not associated with any clinico‐pathological characteristics. In survival outcome, DLL3 was correlated with worse OS, which suggests the prognostic role of DLL3 in ES‐SCLC.https://doi.org/10.1111/1759-7714.15522DLL3 proteinhumanprognosissmall cell lung carcinoma |
| spellingShingle | Hohyung Nam Soon‐Hee Jung Jii Bum Lee Jee Hyun Kong Seungtaek Lim Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy Thoracic Cancer DLL3 protein human prognosis small cell lung carcinoma |
| title | Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy |
| title_full | Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy |
| title_fullStr | Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy |
| title_full_unstemmed | Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy |
| title_short | Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy |
| title_sort | impact of dll3 expression as prognostic factor in extensive stage of small cell lung cancer treated with first line chemotherapy |
| topic | DLL3 protein human prognosis small cell lung carcinoma |
| url | https://doi.org/10.1111/1759-7714.15522 |
| work_keys_str_mv | AT hohyungnam impactofdll3expressionasprognosticfactorinextensivestageofsmallcelllungcancertreatedwithfirstlinechemotherapy AT soonheejung impactofdll3expressionasprognosticfactorinextensivestageofsmallcelllungcancertreatedwithfirstlinechemotherapy AT jiibumlee impactofdll3expressionasprognosticfactorinextensivestageofsmallcelllungcancertreatedwithfirstlinechemotherapy AT jeehyunkong impactofdll3expressionasprognosticfactorinextensivestageofsmallcelllungcancertreatedwithfirstlinechemotherapy AT seungtaeklim impactofdll3expressionasprognosticfactorinextensivestageofsmallcelllungcancertreatedwithfirstlinechemotherapy |